FBXO17: A Potential Drug Target and Biomarker (G115290)

Target Name: FBXO17

NCBI ID: G115290

FBXO17

FBXO17: A Potential Drug Target and Biomarker

Fbinding proteins, also known as F-protein, are a family of transmembrane proteins that play a crucial role in various cellular processes. One of the most well-known F-proteins is the FBXO17 protein, which is a key regulator of the actinin complex in the cytosol. This protein has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The FBXO17 protein is composed of 254 amino acid residues and has a calculated molecular weight of 31 kDa. It is expressed in various tissues, including muscle, heart, brain, and liver. FBXO17 functions as a scaffold protein that helps regulate the actinin complex, which is responsible for the proper functioning of actin filaments in the cytosol. This protein plays a vital role in the regulation of cytoskeletal organization and in the maintenance of cell mechanical forces.

FBXO17 has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It has been shown to regulate the sprouting angiogenesis that occurs during the development of new blood vessels. FBXO17 has also been shown to be involved in the regulation of the cytoskeleton organization, which is essential for the proper functioning of the cell.

In addition to its role in cytoskeletal organization, FBXO17 has also been shown to play a role in the regulation of cell survival. Studies have shown that FBXO17 can induce the expression of cell survival genes, such as p53, which is a well-known regulator of DNA damage repair. This suggests that FBXO17 may play a role in the regulation of cell survival and that it may be a potential drug target for diseases that are characterized by the suppression of cell survival.

FBXO17 has also been shown to be involved in the regulation of inflammation. Studies have shown that FBXO17 can modulate the expression of pro-inflammatory genes, such as nuclear factor kappa B (NF-kappa-B), which is a well-known regulator of inflammation. This suggests that FBXO17 may play a role in the regulation of inflammation and that it may be a potential biomarker for diseases that are characterized by inflammation.

In conclusion, FBXO17 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its role in the regulation of cytoskeletal organization, cell survival, and inflammation makes it an attractive target for drug development. Further research is needed to fully understand the function of FBXO17 and to determine its potential as a drug target and biomarker.

Protein Name: F-box Protein 17

Functions: Substrate-recognition component of the SCF (SKP1-CUL1-F-box protein)-type E3 ubiquitin ligase complex. Able to recognize and bind denatured glycoproteins, which are modified with complex-type oligosaccharides. Also recognizes sulfated glycans. Does not bind high-mannose glycoproteins

The "FBXO17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets